A practical framework categorizes TKIs into three classes to guide adjuvant use. Class 1 (e.g., osimertinib, alectinib) has high efficacy and low toxicity, making extrapolation easy. Class 2 (e.g., BRAF/MET inhibitors) has moderate efficacy and higher toxicity, requiring trials. Class 3 (e.g., KRAS inhibitors) has lower activity and needs trials.

Data shows the next-generation KRAS G12C inhibitor deveracib achieves a median progression-free survival (PFS) of 13.8 months as a single agent. This represents a major leap forward, more than doubling the 5-6 month PFS seen with first-generation drugs like sotorasib and adagrasib, signaling a new efficacy benchmark.

Despite both being options, experts favor the TKI zongertinib for second-line treatment of HER2-mutant NSCLC. This preference is driven by zongertinib's higher response rates (~71%) and longer progression-free survival in this setting, coupled with a better side effect profile compared to the ADC trastuzumab-deruxtecan (TDXD).

With a 90% response rate and median progression-free survival approaching four years, taletrectinib is now the preferred frontline treatment for ROS1-positive NSCLC. Its efficacy and manageable safety profile, primarily transient GI toxicity and manageable LFT elevation, surpass older-generation inhibitors.

The FLORA two study's overall survival benefit was so compelling that clinicians should now default to osimertinib plus chemotherapy for most first-line EGFR-mutant NSCLC patients, only opting out for specific reasons like comorbidities or patient preference.

Even if randomized trials show zongertinib's efficacy is merely comparable to chemoimmunotherapy, its significantly milder safety profile—especially its lack of cardiac toxicity and manageable side effects—is expected to make it the preferred first-line choice. Patient quality of life and tolerability are becoming decisive factors in treatment selection.

Due to a 10-11 month overall survival benefit shown in the FLORA two regimen, leading oncologists now consider osimertinib plus chemotherapy the standard first-line treatment for metastatic EGFR-mutant NSCLC. Monotherapy is reserved only for patients who cannot tolerate or refuse chemotherapy.

In ROS1-positive NSCLC, starting with older TKIs before newer agents like Repotrectinib dramatically worsens outcomes. Median overall survival has not been reached after 5 years for TKI-naive patients but drops to just 25 months for those pre-treated with another TKI. This starkly quantifies the critical importance of using the most effective treatment first.

The recent first-line FDA approval of the oral TKI zungertinib fundamentally alters the treatment paradigm for HER2-mutant non-small cell lung cancer. This shifts the standard of care away from initial platinum-based chemotherapy, forcing oncologists to reconsider the sequencing of TKIs, antibody-drug conjugates, and chemotherapy.